Rumor: Sam Altman backs Pharia Health, transcranial magnetic stimulation (TMS) protocol startup

Why it matters

Compressing TMS into a single day aims to reduce time and friction for operators who cannot commit to weeks-long clinic schedules. If the outcomes hold, a $995 price point plus optional $200 monthly maintenance could make interventional mental health more accessible for busy professionals.

We have been tipped that Sam Altman is backing San Francisco-based Pharia Health, which is offering a one-day, accelerated transcranial magnetic stimulation protocol in San Francisco, priced at $995 for a Foundation Day, with an optional $200 per month maintenance program. The company positions the program for high-performing professionals seeking focus, follow-through, and calm without feeling dulled, and markets the protocol as paired with d-cycloserine, according to Pharia Health.

Pharia describes TMS as short patterns of magnetic pulses that non-invasively modulate activity in specific brain regions - the circuits that shape drive, calm, focus, and presence - shifting underlying neural patterns rather than targeting thoughts or behavior. Stimulation is applied to points on the cortex that correlate with brain networks governing patterns of thinking and feeling, with targets selected based on a person's goals. Protocols are personalized with clinician-selected target, dosage, and timing based on existing evidence and need, and the device is calibrated to an individual's biology.

The company says TMS works through repetition of the same circuits across many pulses until baseline activity shifts. Traditional courses spread sessions over weeks; Pharia compresses into a single day, aiming to deliver enough stimulation to move the baseline, with reported effects that hold for 6 to 8 weeks for most people.

Pharia highlights three primary targets chosen per goal:

• Left dorsal prefrontal cortex: drive and executive function; associated with improved motivation, clearer decision-making, and less friction between thinking and doing.
• Right dorsal prefrontal cortex: focus and cognitive control.
• Dorsomedial prefrontal cortex: presence and emotional resilience.

The site lists common shifts people describe:

• Clearer thinking.
• Improved focus.
• Emotional steadiness.
• Better recovery.

Pharia frames safety and standards as:

• FDA-cleared devices, delivered by trained technicians.
• Clinical oversight by licensed medical professionals.
• Safe and well-tolerated across diverse patient populations in clinical trials; a light tapping sensation or clicking sound is brief and expected.

Onboarding includes AI conversations, wearables integration, and a physician consult to personalize the plan, the site says. The Foundation Day comprises a full-day, personalized TMS protocol, followed by a post-treatment integration session and a 30-day check-in. Pharia says most people notice changes within 24 to 72 hours that last 6 to 8 weeks. The Studio maintenance option offers a roughly 90-minute monthly baseline session, with additional sessions as clinically appropriate.

Pharia points to published and in-progress research underpinning its approach. A 2025 real-world analysis of a single-day TMS regimen reported that nearly 80% of participants experienced significant reduction in depression and anxiety symptoms at three months, and 50% through six months (ScienceDirect). Stanford's accelerated high-dose protocol was tolerated and safe in treatment-resistant depression, with 86% of participants meeting remission criteria at five weeks (American Journal of Psychiatry). A Harvard-led head-to-head randomized trial found symptom-specific brain circuit stimulation yielded meaningfully different results in patients sharing the same diagnosis, supporting personalized, symptom-led targeting (ResearchGate).

Pharia is led by clinicians and researchers with neuromodulation and mental health backgrounds. Co-founder Jeeshan Chowdhury, MD, PhD, studied at Oxford as a Rhodes Scholar and previously founded ListRunner and Journey Colab. Co-founder Anna Martirosyan worked on psychedelic medicine at Journey Colab and in healthcare and software investing at Bain & Co., and holds BA degrees in Psychology and Economics from UC Berkeley. Medical Director David Carreon, MD, is a board-certified psychiatrist trained at Stanford who founded Acacia Clinics and has conducted research in Stanford's Etkin Neuroscience Lab. Clinics Director Nathan Meng, MD, trained at Stanford, co-founded Acacia Clinics, and held roles at Ameda and Embrace.

Pharia lists the service as HSA/FSA eligible. It is not covered by insurance; the company provides a superbill for potential out-of-network reimbursement but notes that repayment is not guaranteed.

Readers can review the company's summary of the science and references at The Science and Explore the research. Prospective clients can Get Started.